Developer docs
API playgroundTry for free, no card

Search company profiles

SubjectWell

Full company profile

uuid0000cvo

Namestring
SubjectWell
Legal namestring
Subject Well, Inc.
Websiteurl
subjectwell.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

SubjectWell is an Austin, Texas-based patient recruitment and commercial solutions platform serving pharmaceutical sponsors, contract research organizations (CROs), clinical research sites, and brand marketers running clinical trials. The company's core offering is a marketplace-mediated recruitment service — Study Connect (tiered patient recruitment), Direct Connect (rapid marketplace-based patient matching), and Brand Connect (commercial-stage patient marketing) — combined with a globally distributed team of 100+ clinically trained, multilingual Patient Companions supporting patients in 36 countries across 22+ languages. At the center is the OneView recruitment portal, which centralizes referral management, integrates with sponsor and site CTMS systems via API, and applies AI/ML predictive models to match patients to trial criteria, forecast enrollment timelines, and quantify protocol burden through proprietary Site Burden Index and Patient Burden Index frameworks. The company reports a Patient Network of 13M+ patients (47% patients of color) with 300,000 added monthly, and claims 1,400+ studies completed, 15,500+ sites served, 500,000+ patient referrals delivered, and an average 30% reduction in enrollment timelines (≈6 months), with 48% of work involving rescue of trials already behind on enrollment.

SubjectWell's business model combines project-based professional services fees from pharma sponsors and CROs (the dominant stream) with subscription/recurring commercial revenue from Brand Connect and Treatment+ solutions targeting pharmaceutical brand marketers, medical device companies, and agencies. Go-to-market is sales-led, with dedicated Customer Success Managers and configurable tiered solutions; pricing is quote-based and not publicly disclosed. Geographically, the company operates as a remote-first organization with offices in Austin, Cape Town, and Munich, serving 102 countries.

The company's ownership history reflects a clear strategic trajectory: a $35M Series B in October 2022 (led by Asset Management Ventures with Bertelsmann), followed by acquisitions of PatientCentra (Nov 2023, rare disease/oncology) and Trials24 (Sep 2024, digital recruitment), a WindRose Health Investors take-private in April 2024, the OneView launch and SubjectWell 2.0 rebrand in February 2025, and a January 2026 merger with Clariness — backed by the same PE firm — to form a combined global full-service patient recruitment platform operating under the Clariness name, with 42,000+ cumulative randomizations across 400+ indications and 60+ country coverage. Fred Martin, the prior CEO, transitioned to a board role, and Jim Corrigan was appointed CEO of the merged entity.

Short descriptiontext

SubjectWell is an Austin-based patient recruitment marketplace serving pharmaceutical sponsors, CROs, and clinical research sites globally, combining a 13M+ patient database, AI/ML matching, and a multilingual Patient Companion team across 36 countries to accelerate trial enrollment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial recruitment, patient recruitment platform, clinical research technology, patient engagement services, clinical trial enrollment
Industry2 codes
PRIMARYHLAGACAB
Site Identification & Feasibility
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Patient Recruitment
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Patient Recruitment Services
TypeProfessional Services
Description

Service contracts with pharmaceutical sponsors and CROs for patient recruitment solutions. Solutions include Study Connect (tiered patient recruitment), services (secondary screening, site support, translations), and technology platform access. Revenue generated through project-based fees or retainer arrangements with pharmaceutical companies conducting clinical trials.

subjectwell.com
2Brand Connect (Commercial Solutions)
TypeSubscription Recurring
Description

Commercial solutions for pharmaceutical brand marketers, medical device companies, and agencies to market products directly to condition-specific patient populations through SubjectWell's engaged Patient Network and extensive media network.

subjectwell.com
3Treatment+ Solutions
TypeSubscription Recurring
Description

Commercial solutions connecting patients with new treatment and therapy options, reinforcing brand touchpoints with patients throughout their treatment journey to foster loyalty and strengthen patient-brand relationships.

subjectwell.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Study Connect offers three flexible tiers to match clinical study needs
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed. Tiers designed for studies from simple to complex, with configurable attributes supporting every patient, study, geography, and therapeutic area.

subjectwell.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Study Connect
Description

Patient recruitment solution available in three flexible tiers for clinical studies

subjectwell.com
+5 more records
Core offering1 text field

SubjectWell is a risk-free clinical trials marketplace that recruits patients for pharmaceutical sponsors, CROs, and research sites. It combines the SubjectWell+ platform (OneView portal, AI/ML predictive matching, and a 13M+ Patient Network) with human Patient Companions to deliver Study Connect and Direct Connect recruitment solutions, plus Brand Connect for pharma commercial campaigns. Services span protocol feasibility, secondary screening, site support, and Full-Site Support across 102 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 30% enrollment acceleration (average of 6 months reduction in recruitment time)
+4 more records
Product overview1 text field

SubjectWell operates as a patient recruitment and commercial solutions platform organized around the SubjectWell+ platform architecture. The core portfolio consists of Study Connect (patient recruitment solution in three flexible tiers), Direct Connect (rapid patient recruitment through a marketplace model), and Brand Connect (commercial solutions for pharmaceutical marketing). The OneView Portal serves as the centralized technology platform providing recruitment oversight, real-time insights, and AI/ML-powered patient matching. The company maintains a Patient Network of 13M+ patients and provides complementary services including Patient Companions, Site Companions, Full-Site Support, Secondary Screening, and Virtual Waiting Room. SubjectWell supports recruitment across 102 countries with Patient Companions available in 36 countries speaking 22+ languages.

Product and service5 records
1Study Connect
CategoryPatient recruitment solution
Description

Proven patient recruitment solution available in three flexible tiers that matches clinical study needs by combining SubjectWell technology, Patient Companions, creative expertise, and media network. Reduces enrollment time by 30% and produces quality referrals for US, global, and multi-country studies while minimizing site burden.

2Direct Connect
CategoryRapid patient recruitment marketplace
Description

Rapid patient recruitment solution leveraging SubjectWell's patient access marketplace to connect patients within study-appropriate geographies directly to study websites for registration and prescreening, using machine learning to match by condition and location.

3OneView Portal
CategoryRecruitment management platform
Description

Centralized recruitment management platform that provides real-time insights for faster decision-making across all referral sources, sites, and studies. Integrates with existing systems such as CTMS, enhances workflow management, and uses AI/ML predictive models for targeted patient matching and personalized outreach strategies.

4Brand Connect
CategoryPharma commercial marketing solution
Description

Commercial solution enabling pharmaceutical brand marketers, medical device companies, and agencies to market healthcare products directly to condition-specific patient populations through SubjectWell's engaged Patient Network and media network, including Treatment+ Solutions for ongoing brand touchpoints.

5SubjectWell+ Platform
CategoryIntegrated patient recruitment platform
Description

Comprehensive technology platform that delivers patient recruitment and site enablement solutions, paired with advanced commercial capabilities to connect patients with clinical trials and new treatments. Combines the Patient Network database, OneView portal, AI/ML predictive models, and multi-channel engagement technology.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-26
Description

SubjectWell merged with Clariness in January 2026 to form one of the largest global full-service patient recruitment platforms for clinical trials. The combined entity operates under the Clariness name, with support for clinical trials in over 60 countries, having delivered 42,000+ randomizations across 400+ indications and partnered with 10,000+ research sites globally. Transaction was led by WindRose Health Investors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

SubjectWell acquired Trials24 in September 2024 to expand global patient engagement capabilities. The acquisition aims to enhance SubjectWell's reach, diversity, and technological offerings in clinical trial recruitment across multiple geographies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-02
Description

SubjectWell acquired PatientCentra in November 2023 to expand global patient recruitment capabilities, particularly for rare diseases and oncology research. PatientCentra brought 15 years of experience in digital patient recruitment across five continents, enabling end-to-end recruitment support for international clinical studies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnerships with patient advocacy organizations for rare disease awareness campaigns, community engagement, and patient education across various therapeutic areas.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Healthcare provider networks and physician referral systems that direct patients toward clinical trial opportunities and support patient recruitment efforts.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Extensive media network including retail pharmacies, labs, claims data providers, genomics companies, and digital health platforms that enable multi-channel patient outreach beyond traditional search and social.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Antidote (Lumanity)
TypeDirect peer
Description

Antidote, now part of Lumanity, is a patient recruitment marketplace connecting patients to clinical trials — directly competing with SubjectWell's core Direct Connect / Study Connect offerings across sponsors, CROs, and sites.

TypeDirect peer
Description

Trialbee is a patient recruitment and engagement platform using data-driven targeting to match patients to trials. It competes head-to-head with SubjectWell's Study Connect and Direct Connect products across global sponsor and CRO accounts.

3Deep 6 AI
TypeDirect peer
Description

Deep 6 AI applies AI to electronic medical record data to accelerate patient identification and recruitment for clinical trials, competing with SubjectWell's AI/ML predictive matching and OneView platform.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO with embedded patient recruitment, real-world evidence, and clinical technology capabilities — a broad incumbent that competes with SubjectWell via bundled enterprise offerings.

TypeBroad incumbent
Description

ICON is a top global CRO offering integrated patient recruitment and feasibility services to sponsors — a broad incumbent competing for the same enterprise trial recruitment budgets as SubjectWell.

TypeBroad incumbent
Description

Parexel is a major global CRO with patient recruitment, site services, and decentralized trial capabilities, competing with SubjectWell across large multi-country trials in oncology and rare disease.

TypeBroad incumbent
Description

Medidata provides clinical trial technology platforms (EDC, RTSM, eCOA) and increasingly patient-centric trial solutions — a broad incumbent competing with SubjectWell's technology layer for sponsor technology and data spend.

TypeBroad incumbent
Description

Veeva provides clinical, regulatory, and quality software for life sciences, including Veeva Vault CTMS and eTMF. It competes with SubjectWell for sponsor technology spend and is increasingly adjacent to patient recruitment workflows.

TypeEmerging player
Description

Curebase is an emerging decentralized clinical trial platform with patient recruitment and virtual site capabilities — overlapping with SubjectWell's decentralized trial support and global recruitment ambitions.

TypeOthers
Description

WCG provides clinical trial services including IRB review, site support, and patient engagement tools — an adjacent ecosystem participant whose site and sponsor relationships overlap with SubjectWell's customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SubjectWell

Clinical Trial Patient Recruitmentsubjectwell.com

SubjectWell is an Austin-based patient recruitment marketplace serving pharmaceutical sponsors, CROs, and clinical research sites globally, combining a 13M+ patient database, AI/ML matching, and a multilingual Patient Companion team across 36 countries to accelerate trial enrollment.

What SubjectWell does

SubjectWell is an Austin, Texas-based patient recruitment and commercial solutions platform serving pharmaceutical sponsors, contract research organizations (CROs), clinical research sites, and brand marketers running clinical trials. The company's core offering is a marketplace-mediated recruitment service — Study Connect (tiered patient recruitment), Direct Connect (rapid marketplace-based patient matching), and Brand Connect (commercial-stage patient marketing) — combined with a globally distributed team of 100+ clinically trained, multilingual Patient Companions supporting patients in 36 countries across 22+ languages. At the center is the OneView recruitment portal, which centralizes referral management, integrates with sponsor and site CTMS systems via API, and applies AI/ML predictive models to match patients to trial criteria, forecast enrollment timelines, and quantify protocol burden through proprietary Site Burden Index and Patient Burden Index frameworks. The company reports a Patient Network of 13M+ patients (47% patients of color) with 300,000 added monthly, and claims 1,400+ studies completed, 15,500+ sites served, 500,000+ patient referrals delivered, and an average 30% reduction in enrollment timelines (≈6 months), with 48% of work involving rescue of trials already behind on enrollment.

SubjectWell's business model combines project-based professional services fees from pharma sponsors and CROs (the dominant stream) with subscription/recurring commercial revenue from Brand Connect and Treatment+ solutions targeting pharmaceutical brand marketers, medical device companies, and agencies. Go-to-market is sales-led, with dedicated Customer Success Managers and configurable tiered solutions; pricing is quote-based and not publicly disclosed. Geographically, the company operates as a remote-first organization with offices in Austin, Cape Town, and Munich, serving 102 countries.

The company's ownership history reflects a clear strategic trajectory: a $35M Series B in October 2022 (led by Asset Management Ventures with Bertelsmann), followed by acquisitions of PatientCentra (Nov 2023, rare disease/oncology) and Trials24 (Sep 2024, digital recruitment), a WindRose Health Investors take-private in April 2024, the OneView launch and SubjectWell 2.0 rebrand in February 2025, and a January 2026 merger with Clariness — backed by the same PE firm — to form a combined global full-service patient recruitment platform operating under the Clariness name, with 42,000+ cumulative randomizations across 400+ indications and 60+ country coverage. Fred Martin, the prior CEO, transitioned to a board role, and Jim Corrigan was appointed CEO of the merged entity.

SubjectWell firmographics

Firmographics
Name
SubjectWell
Legal name
Subject Well, Inc.
Website
https://subjectwell.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
SubjectWell is an Austin-based patient recruitment marketplace serving pharmaceutical sponsors, CROs, and clinical research sites globally, combining a 13M+ patient database, AI/ML matching, and a multilingual Patient Companion team across 36 countries to accelerate trial enrollment.
Ownership category
akta.pro rank

SubjectWell industry classification

Industry
Product category
Clinical Trial Patient Recruitment
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGACAB
Site Identification & Feasibility
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Clinical trial recruitment
  • Patient recruitment platform
  • Clinical research technology
  • Patient engagement services
  • Clinical trial enrollment

Where SubjectWell is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices3 records

Markets served

SubjectWell business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Patient Recruitment Services: Service contracts with pharmaceutical sponsors and CROs for patient recruitment solutions. Solutions include Study Connect (tiered patient recruitment), services (secondary screening, site support, translations), and technology platform access. Revenue generated through project-based fees or retainer arrangements with pharmaceutical companies conducting clinical trials.
  2. Brand Connect (Commercial Solutions): Commercial solutions for pharmaceutical brand marketers, medical device companies, and agencies to market products directly to condition-specific patient populations through SubjectWell's engaged Patient Network and extensive media network.
  3. Treatment+ Solutions: Commercial solutions connecting patients with new treatment and therapy options, reinforcing brand touchpoints with patients throughout their treatment journey to foster loyalty and strengthen patient-brand relationships.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractStudy Connect offers three flexible tiers to match clinical study needs

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

SubjectWell product offering

Product offering

Core offering

SubjectWell is a risk-free clinical trials marketplace that recruits patients for pharmaceutical sponsors, CROs, and research sites. It combines the SubjectWell+ platform (OneView portal, AI/ML predictive matching, and a 13M+ Patient Network) with human Patient Companions to deliver Study Connect and Direct Connect recruitment solutions, plus Brand Connect for pharma commercial campaigns. Services span protocol feasibility, secondary screening, site support, and Full-Site Support across 102 countries.

Product overview

SubjectWell operates as a patient recruitment and commercial solutions platform organized around the SubjectWell+ platform architecture. The core portfolio consists of Study Connect (patient recruitment solution in three flexible tiers), Direct Connect (rapid patient recruitment through a marketplace model), and Brand Connect (commercial solutions for pharmaceutical marketing). The OneView Portal serves as the centralized technology platform providing recruitment oversight, real-time insights, and AI/ML-powered patient matching. The company maintains a Patient Network of 13M+ patients and provides complementary services including Patient Companions, Site Companions, Full-Site Support, Secondary Screening, and Virtual Waiting Room. SubjectWell supports recruitment across 102 countries with Patient Companions available in 36 countries speaking 22+ languages.

Differentiator

Problem solved

Functional benefit

Brands

  • Study Connect: Patient recruitment solution available in three flexible tiers for clinical studies
  • Direct Connect
  • Brand Connect
  • SubjectWell+ Platform
  • OneView
  • Patient Network

Products and services

  • Study Connect Proven patient recruitment solution available in three flexible tiers that matches clinical study needs by combining SubjectWell technology, Patient Companions, creative expertise, and media network. Reduces enrollment time by 30% and produces quality referrals for US, global, and multi-country studies while minimizing site burden.
  • Direct Connect Rapid patient recruitment solution leveraging SubjectWell's patient access marketplace to connect patients within study-appropriate geographies directly to study websites for registration and prescreening, using machine learning to match by condition and location.
  • OneView Portal Centralized recruitment management platform that provides real-time insights for faster decision-making across all referral sources, sites, and studies. Integrates with existing systems such as CTMS, enhances workflow management, and uses AI/ML predictive models for targeted patient matching and personalized outreach strategies.
  • Brand Connect Commercial solution enabling pharmaceutical brand marketers, medical device companies, and agencies to market healthcare products directly to condition-specific patient populations through SubjectWell's engaged Patient Network and media network, including Treatment+ Solutions for ongoing brand touchpoints.
  • SubjectWell+ Platform Comprehensive technology platform that delivers patient recruitment and site enablement solutions, paired with advanced commercial capabilities to connect patients with clinical trials and new treatments. Combines the Patient Network database, OneView portal, AI/ML predictive models, and multi-channel engagement technology.

Quantifiable outcome

  • 30% enrollment acceleration (average of 6 months reduction in recruitment time)
  • +4 more outcomes

Companies that use SubjectWell

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

SubjectWell technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature8 records

SubjectWell partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • ClarinesscoreStrategic or Co-development Partner · 26 January 2026SubjectWell merged with Clariness in January 2026 to form one of the largest global full-service patient recruitment platforms for clinical trials. The combined entity operates under the Clariness name, with support for clinical trials in over 60 countries, having delivered 42,000+ randomizations across 400+ indications and partnered with 10,000+ research sites globally. Transaction was led by WindRose Health Investors.
  • Trials24coreStrategic or Co-development Partner · 17 September 2024SubjectWell acquired Trials24 in September 2024 to expand global patient engagement capabilities. The acquisition aims to enhance SubjectWell's reach, diversity, and technological offerings in clinical trial recruitment across multiple geographies.
  • PatientCentracoreStrategic or Co-development Partner · 2 November 2023SubjectWell acquired PatientCentra in November 2023 to expand global patient recruitment capabilities, particularly for rare diseases and oncology research. PatientCentra brought 15 years of experience in digital patient recruitment across five continents, enabling end-to-end recruitment support for international clinical studies.
  • Patient Advocacy GroupsminorStrategic or Co-development PartnerPartnerships with patient advocacy organizations for rare disease awareness campaigns, community engagement, and patient education across various therapeutic areas.
  • Healthcare ProvidersminorChannel Partner/ Reseller/ DistributorHealthcare provider networks and physician referral systems that direct patients toward clinical trial opportunities and support patient recruitment efforts.
  • Media and Digital PartnersminorChannel Partner/ Reseller/ DistributorExtensive media network including retail pharmacies, labs, claims data providers, genomics companies, and digital health platforms that enable multi-channel patient outreach beyond traditional search and social.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

SubjectWell competitors and assessment

Company assessment

Direct peers

  • Antidote (Lumanity): Antidote, now part of Lumanity, is a patient recruitment marketplace connecting patients to clinical trials — directly competing with SubjectWell's core Direct Connect / Study Connect offerings across sponsors, CROs, and sites.
  • Trialbee: Trialbee is a patient recruitment and engagement platform using data-driven targeting to match patients to trials. It competes head-to-head with SubjectWell's Study Connect and Direct Connect products across global sponsor and CRO accounts.
  • Deep 6 AI: Deep 6 AI applies AI to electronic medical record data to accelerate patient identification and recruitment for clinical trials, competing with SubjectWell's AI/ML predictive matching and OneView platform.

Broad incumbents

  • IQVIA: IQVIA is the world's largest CRO with embedded patient recruitment, real-world evidence, and clinical technology capabilities — a broad incumbent that competes with SubjectWell via bundled enterprise offerings.
  • ICON plc: ICON is a top global CRO offering integrated patient recruitment and feasibility services to sponsors — a broad incumbent competing for the same enterprise trial recruitment budgets as SubjectWell.
  • Parexel: Parexel is a major global CRO with patient recruitment, site services, and decentralized trial capabilities, competing with SubjectWell across large multi-country trials in oncology and rare disease.
  • Medidata (Dassault Systèmes): Medidata provides clinical trial technology platforms (EDC, RTSM, eCOA) and increasingly patient-centric trial solutions — a broad incumbent competing with SubjectWell's technology layer for sponsor technology and data spend.
  • Veeva Systems: Veeva provides clinical, regulatory, and quality software for life sciences, including Veeva Vault CTMS and eTMF. It competes with SubjectWell for sponsor technology spend and is increasingly adjacent to patient recruitment workflows.

Emerging players

  • Curebase: Curebase is an emerging decentralized clinical trial platform with patient recruitment and virtual site capabilities — overlapping with SubjectWell's decentralized trial support and global recruitment ambitions.

Others

  • WCG (WIRB-Copernicus Group): WCG provides clinical trial services including IRB review, site support, and patient engagement tools — an adjacent ecosystem participant whose site and sponsor relationships overlap with SubjectWell's customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

SubjectWell social profiles

Digital presence

SubjectWell compliance and trust

Trust signal

Compliance3 records

SubjectWell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SubjectWell leadership team

Management profile

Number of profiles

Profiles15 records

SubjectWell subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

SubjectWell funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SubjectWell M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SubjectWell

What does SubjectWell do?

SubjectWell is a risk-free clinical trials marketplace that recruits patients for pharmaceutical sponsors, CROs, and research sites. It combines the SubjectWell+ platform (OneView portal, AI/ML predictive matching, and a 13M+ Patient Network) with human Patient Companions to deliver Study Connect and Direct Connect recruitment solutions, plus Brand Connect for pharma commercial campaigns. Services span protocol feasibility, secondary screening, site support, and Full-Site Support across 102 countries.

Is SubjectWell a public or private company?

SubjectWell is a private company. It is classified as private equity controlled and is currently operating.

When was SubjectWell founded?

SubjectWell was founded in 2015. It employs 101 to 250 people.

Where is SubjectWell based?

SubjectWell is headquartered in Austin, United States, in the North America region.

How does SubjectWell make money?

Three revenue lines are on record. Patient Recruitment Services are the primary driver. The others are brand Connect (Commercial Solutions) and treatment+ Solutions.

Who are SubjectWell's main competitors?

Direct peers on record are Antidote (Lumanity), Trialbee and Deep 6 AI. Broad incumbents are IQVIA, ICON plc, Parexel, Medidata (Dassault Systèmes) and Veeva Systems. Curebase is listed as an emerging player. WCG (WIRB-Copernicus Group) is listed as an others.

Does SubjectWell have an API?

Yes. SubjectWell offers API integrations that enable CTMS and other system integrations to deliver referrals directly to customer systems. The API provides seamless access to referral data in a way that integrates best with customer workflows, eliminating time associated with fixing duplicate data entries and errors. Developer documentation is at client.subjectwell.com.

What industry is SubjectWell in?

SubjectWell's product category is Clinical Trial Patient Recruitment. Its primary akta.pro industry code is HLAGACAB, Site Identification & Feasibility, with a secondary code of HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Clariness And SubjectWell Merge To Form Full-Service Patient Recruitment PlatformClariness and SubjectWell have announced a merger to form one of the largest global full-service patient recruitment platforms for clinical trials, with the transaction led by private equity firm WindRose Health Investors. The combined organization, operating under the Clariness name, will support clinical trials across more than 60 countries, partnering with over 10,000 research sites and having delivered more than 42,000 randomizations. The merger aims to accelerate clinical trial timelines and improve recruitment performance by integrating technology, patient databases, and marketing capabilities under a unified platform.citybizFairmount Partners Advises Clariness on its Merger with SubjectWell to Form Global, Full-Service Patient Recruitment PlatformClariness and SubjectWell announced their merger to form one of the largest global full-service patient recruitment platforms for clinical trials, with the combined entity operating under the Clariness name. The transaction was led by WindRose Health Investors, which previously acquired SubjectWell in April 2024. The merged company will support clinical trials in over 60 countries, having delivered 42,000+ randomizations across 400+ indications and partnered with 10,000+ research sites globally.PR NewswireClariness and SubjectWell Merge to Form Global, Full-Service Patient Recruitment PlatformClariness and SubjectWell announced their merger to form a global patient recruitment platform for clinical trials, with the transaction led by private equity firm WindRose Health Investors. The combined entity will operate under the Clariness name and claims to support clinical trials across 60+ countries, having delivered 42,000+ randomizations and partnered with 10,000+ research sites globally. The merged company aims to set industry standards in patient recruitment while accelerating clinical research and expanding patient access to clinical trials worldwide.PR NewswireSubjectWell Unveils New Science-Driven Framework to Transform Protocol Design, Recruitment, Engagement, and RetentionSubjectWell, the largest global patient experience platform for clinical trials, announced a new science-driven framework that integrates Patient Burden Index (PBI), Site Burden Index (SBI), and standards-of-care data across the clinical trial lifecycle. The framework enables sponsors to better forecast feasibility, design recruitment strategies matched to protocol complexity, and improve patient and site experiences. The approach is now available for all new sponsor engagements globally.PR NewswireSubjectWell Wins 2025 GDUSA Health + Wellness Design Award for Brand ReinventionSubjectWell, a patient experience platform for clinical trial recruitment based in Austin, Texas, was named a winner in the 2025 GDUSA Health + Wellness Design Awards for brand reinvention, recognizing the top 10% of over 2,400 entries in the national competition's 25th year. The in-house rebrand, completed in four months, delivered measurable gains including a 121% increase in social impressions and a rise in share of voice from 1.4% in early 2024 to 39.4% by April 2025, surpassing all competitors. The rebrand modernized SubjectWell's visual identity, messaging and mission to emphasize empathy and accessibility in connecting patients with clinical studies.SubjectwellPredictability starts with better site supportSubjectWell and Rovia Clinical Research highlighted how integrated site support services, including patient companions and unified portals like OneView, improve clinical trial retention and predictability. The companies reported that these interventions reduced time-to-randomization by 38% and increased contact rates by 25.7% in recent studies.CcrpsTop 75 Clinical Trial Patient Recruitment Companies & Tech Solutions (2025 Mega List)The article presents a guide for clinical trial recruiters on optimizing patient recruitment strategies using various technology solutions and standard operating procedures. It highlights specific tools such as Deep 6 AI, SubjectWell, Medable, and Science 37, advising users to integrate them with Good Clinical Practice (GCP) compliance frameworks. The content serves as an instructional resource rather than reporting on a specific corporate event or transaction.TracxnTop Companies in Clinical Trial Patient Recruitment (Oct, 2025)The article presents a ranked list of top startups in the clinical trial patient recruitment sector, highlighting market trends such as an average of 12 new companies launched annually over the past decade. It details key metrics for leading firms including Evidation, myTomorrows, Dyania Health, and SubjectWell, covering their funding stages, total capital raised, and core platform functionalities. The report also notes that several of these industry players were founded by alumni from prestigious institutions like Columbia University and MIT.PR NewswireSubjectwell Peer-Reviewed Paper Shows Major Diagnostic Gap In Dysmenorrhea; Direct-To-Patient Outreach Reaches Women Missed By Traditional CareSubjectWell published peer-reviewed research in the Journal of Medical Internet Research showing a significant diagnostic gap for dysmenorrhea among women in Germany, Austria, and Poland, with only 4.6% of symptomatic respondents receiving a formal diagnosis despite 88.5% reporting pain levels of 6/10 or higher. The study, funded by Bionorica SE, surveyed 3,546 women via targeted Google and Facebook campaigns and found that direct-to-patient digital outreach achieved 94.6% specificity in identifying women meeting dysmenorrhea symptom criteria. The findings reinforce SubjectWell's evidence-driven patient recruitment approach and suggest digital strategies can effectively engage underserved populations for clinical trial participation.